Introducing the Discussion on Duvelisib in Peripheral T-Cell Lymphoma

Jonathan Brammer, MD, of The Ohio State University, and Pier Luigi Zinzani, MD, of the University of Bologna, open a discussion devoted to duvelisib in peripheral T-cell lymphoma. Brammer introduces himself as a researcher focused on T-cell malignancies, and Zinzani notes his work as a hematologist with broad experience across lymphoma subtypes and a particular interest in peripheral T-cell lymphoma. Together they frame the conversation around a disease setting that has seen little meaningful progress in recent decades, positioning duvelisib as a development of genuine interest for patients with limited options. Brammer establishes that the discussion will center on the agent's activity in T-cell lymphomas and, in particular, on the recently reported results from the PRIMO study. The introduction sets expectations for a wide-ranging exchange that will move from the current treatment landscape through trial data, mechanism, sequencing, and future directions in this rare and challenging group of diseases.